Levels of Inflammatory Markers in the Treatment of Stroke—An SPS3 Ancillary Study "LIMITS"

Completed

Phase N/A Results N/A

References

Related Links

website containing associated parent SPS3 trial information

Sources for Trial Information

Columbia University
ClinicalTrials.gov

Staticmap?size=198x113&sensor=false&zoom=1&markers=45.4988, -122.686&markers=29.7102, -95.3996&markers=43.1935, -77.5878&markers=43.0431, -88.021&markers=25.7914, -80.2125&markers=42.3575, -83.067&markers=44.0221, -92.4667&markers=40.8411, -73.9416&markers=29.508, -98.574&markers=38.6456, -90.4468&markers=43.1225, -77.6254&markers=42.3637, -83.0751&markers=38.0272, -84.504&markers=42.3339, -71.0739&markers=33.5855, -111.792&markers=-2.13803, -79.8643&markers=30.6814, -88.0732&markers=41.5091, -81.609&markers=32.24, -110.946&markers=32.8786, -117.226&markers=38.5816, -121.494&markers=28.0832, -80.6216&markers=41.5994, -93.6232&markers=44.9725, -93.2621&markers=38.6357, -90

View Trial Locations

Recruitment

Enrollment: 1,244
Gender: All
Minimum Age: 30 Years
Accepts Healthy Volunteers: No
48 locations, 7 countries

Principal Investigator

Mitchell S.V. Elkind, MD, MS, FAAN
Columbia University
Oscar Benavente, MD
UTHSC San Antonio (SPS3 Principal Investigator)
Robert Hart, MD
UTHSC San Antonio (SPS3 Principal Investigator)

NCT00579306 ClinicalTrials.gov →